Bolt Biotherapeutics, Inc. - Common Stock (BOLT)
0.4650
-0.0174 (-3.61%)
Bolt Biotherapeutics is a biotechnology company that focuses on developing innovative immunotherapy treatments for cancer
The company utilizes its proprietary platform to create targeted therapies that engage the immune system to recognize and destroy cancerous cells more effectively. By harnessing the power of the body’s own immune response, Bolt aims to improve patient outcomes and provide new options for individuals battling various forms of cancer. Their research and development efforts are directed toward creating novel therapeutic candidates that can advance the field of cancer treatment.
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
BOLT stock results show that Bolt Biotherapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 13, 2024
![](https://investorplace.com/wp-content/uploads/2023/03/foundations-of-wealth-series-img-7-scaled.jpg)
Explore key stocks with analyst uncertainty to avoid amid contrasting global market highs and risky downgrades.
Via InvestorPlace · May 24, 2024
![](https://cdn.benzinga.com/files/images/story/2024/05/15/movers.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · May 15, 2024
![](https://cdn.benzinga.com/files/images/story/2023/roce_image_780.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · March 30, 2023
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_6187.jpeg)
During Friday's morning session, 234 stocks hit new 52-week lows.
Interesting Facts About Today's 52-Week Lows:
The largest company in terms of market cap...
Via Benzinga · April 8, 2022
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · May 15, 2024
![](https://cdn.benzinga.com/files/images/story/2024/05/15/Prague-cz--27-April-2023-Logo-On-Accentu.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · May 15, 2024
![](https://cdn.benzinga.com/files/images/story/2024/05/15/movers-image_3.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · May 15, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · May 15, 2024
![](https://investorplace.com/wp-content/uploads/2021/04/wall-street.jpg)
We are covering the biggest pre-market stock movers for Wednesday with all of the latest happenings worth watching this morning!
Via InvestorPlace · May 15, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
BOLT stock results show that Bolt Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 14, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · May 14, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · April 3, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
BOLT stock results show that Bolt Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 21, 2024
![](https://cdn.benzinga.com/files/images/story/2023/10/02/image21.jpeg?width=1200&height=800&fit=crop)
Gainers AERWINS Technologies Inc. (NASDAQAWIN) shares rose 90.2% to $0.2297 in pre-market trading. Aerwins Technologies is considering strategic alternatives for non-core operations including, not limited to possible sale/other disposition of assets.
Via Benzinga · October 2, 2023
![](/next-assets/images/schema-image-default.png)
Via Benzinga · May 12, 2023
![](https://cdn.benzinga.com/files/images/story/2023/03/30/bolt.png?width=1200&height=800&fit=crop)
Via Benzinga · March 30, 2023
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_882.png?width=1200&height=800&fit=crop)
Via Benzinga · August 11, 2022
![](https://cdn.benzinga.com/files/images/story/2022/08/11/image_5.jpg?width=1200&height=800&fit=crop)
SVB Leerink cut the price target on Bolt Biotherapeutics, Inc. (NASDAQBOLT) from $8 to $4. SVB Leerink analyst Daina Graybosch downgraded the stock from Outperform to Market Perform. Bolt Biotherapeutics shares fell 3.2% to $2.44 in pre-market trading.
Via Benzinga · August 11, 2022
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_13024.jpeg?width=1200&height=800&fit=crop)
Gainers NeuroBo Pharmaceuticals (NASDAQNRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million.
Via Benzinga · July 20, 2022
![](https://cdn.benzinga.com/files/images/story/2022/07/08/image11.jpg?width=1200&height=800&fit=crop)
Gainers United Maritime Corporation (NASDAQUSEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market.
Via Benzinga · July 8, 2022
![](https://cdn.benzinga.com/files/images/story/2022/roce_image_877.jpeg?width=1200&height=800&fit=crop)
Bolt Biotherapeutics (NASDAQBOLT) brought in sales totaling $508.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 16.08%, resulting in a loss of $27.16 million.
Via Benzinga · March 31, 2022
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_3316.jpeg)
Gainers
Soleno Therapeutics (NASDAQSLNO) shares rose 15.7% to $0.37 during Monday's pre-market session. The market value of their outstanding shares is at $29.5...
Via Benzinga · February 28, 2022
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_6909.jpeg)
On Wednesday, 160 companies hit new 52-week lows.
Areas of Significance In Today's 52-Week Lows:
Walt Disney (NYSEDIS) was the largest firm by market cap to set a new...
Via Benzinga · April 20, 2022